Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Autolus Therapeutics ( (AUTL) ) has shared an announcement.
On April 29, 2026, Autolus Therapeutics announced a strategic initiative to streamline operations and cut costs, including a reduction in force that will eliminate about 13% of its workforce across all areas of the business, following employee-related actions that began in the second half of 2025. The restructuring, expected to be largely complete by the third quarter of 2026, will result in estimated charges of about $8 million, but is projected to reduce annual operating expenses by roughly $15 million starting in 2027 while supporting a doubling of product manufacturing capacity in 2026.
The company reaffirmed its financial outlook for 2026, projecting AUCATZYL net product revenue of $120 million to $135 million, up from $74 million in 2025, and signaled an anticipated move to a positive gross margin that would strengthen its path to profitability in its acute lymphoblastic leukemia business. Autolus also indicated that its clinical programs remain on track and, based on expected revenues and current plans, it believes existing cash, cash equivalents and marketable securities will be sufficient to fund operations into the fourth quarter of 2027, underscoring management’s focus on long-term value creation despite near-term headcount reductions.
The most recent analyst rating on (AUTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
The score is held down primarily by weak financial performance (large losses, negative gross profit, and rising cash burn with a shrinking equity cushion). Offsetting this is a relatively constructive earnings outlook with reiterated 2026 revenue guidance and expected positive gross margins, while technicals remain weak-to-neutral and valuation is difficult to assess meaningfully due to negative earnings and no dividend support.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company that develops, manufactures and delivers next-generation programmed T cell therapies for cancer and autoimmune diseases. The company markets AUCATZYL and is advancing a pipeline that includes trials in pediatric relapsed or refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis, targeting both hematological malignancies and solid tumors.
Average Trading Volume: 1,592,015
Technical Sentiment Signal: Strong Sell
Current Market Cap: $377.9M
Learn more about AUTL stock on TipRanks’ Stock Analysis page.